The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.

Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.

View all videos

EHA 2021

The 26th Congress of the European Hematology Association (EHA) 2021
09 - 17 June 2021

@VJHemOnc @tobyeyre82 @EHA_Hematology @icmlugano Watch out for #CollinsConclusions (I need to see some of the on demand stuff first!)

Mark Levis of @KimmelCancerCtr talks on BET and FLT3 inhibitor combination regimens for FLT3-ITD AML: http://ow.ly/y3F950Ff6IZ

@EHA_Hematology #[email protected] #HemOnc #Leusm #Leukemia #AMLsm

FOLL12 update
@StefanoLuminari et al
MRD/PET directed strategy post RCHOP/RB induction vs R-maint in standard arm
n=777
PFS benefit for R-maint arm vs experimental arm in #FL 1L

Complimentary & direct PET-adapted PETReA trial continues to recruit in UK/Australia

#16ICML #lymsm

4
Load More...

EHA 2021

The 26th Congress of the European Hematology Association (EHA) 2021
9-17 June 2021

The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.

Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.

View all videos

@VJHemOnc @tobyeyre82 @EHA_Hematology @icmlugano Watch out for #CollinsConclusions (I need to see some of the on demand stuff first!)

Mark Levis of @KimmelCancerCtr talks on BET and FLT3 inhibitor combination regimens for FLT3-ITD AML: http://ow.ly/y3F950Ff6IZ

@EHA_Hematology #[email protected] #HemOnc #Leusm #Leukemia #AMLsm

FOLL12 update
@StefanoLuminari et al
MRD/PET directed strategy post RCHOP/RB induction vs R-maint in standard arm
n=777
PFS benefit for R-maint arm vs experimental arm in #FL 1L

Complimentary & direct PET-adapted PETReA trial continues to recruit in UK/Australia

#16ICML #lymsm

4
Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter